Human Serum, Pooled, Heat Inactivated, IgG/IgM/IgA Depleted
Pooled human serum, IgG, IgM, and IgA depleted, heat-inactivated, and frozen.
Specifications
Release criteria
Lead time on this item is currently: 2-4 Weeks
Need help? Ask a Specialist Contact UsOR +1 (800) 643-3426
Product Overview
| Species: | Human |
|---|---|
| Product Types: | Serum |
| Source: | OTC Serum |
| Pooling: | Pooled |
| Donor Sex: | Mixed |
| Depletion Process: | IgA Depleted, IgG Depleted, IgM Depleted |
| Processing Method: | Heat Inactivated |
| Physical State: | Frozen Liquid |
| Application Notes: | Suitable for sample dilution, immunoassays, control serum, and various applications requiring serum supplementation. |
| Testing: | CH50: Negative Residual IgG: <3.5% Residual IgM: <3.5% Residual IgA: <3.5% Serum tested negative for infectious disease per FDA guidelines. |
| Storage Conditions: | -70°C or below |
| Shipping Conditions: | Dry ice |
| Packaging: | Cryovial, Poly bottle |
| Expiration: | 1 year from date of receipt when stored continuously at -70°C or below; avoid repeated freeze/thaw. Product quality is guaranteed to meet Pel-Freez Biologicals' specifications for this period when stored as indicated. |
Product Applications
- Serum bactericidal assay
- Opsonophagocytic assay
- Complement-dependent cytotoxicity
- Hemolytic complement assay
- Assay diluent & negative matrix
- Assay controls & calibrators
- Toxicology assays
- Vaccine development
- In vitro diagnostics
Documents & Datasheets
Certificate of Analysis
| Lot | Issued | |
|---|---|---|
| 22448A | Aug 28, 2026 | Download |
| 22448B | Aug 28, 2026 | Download |
| 22448C | Aug 28, 2026 | Download |
| 02248 | Jan 30, 2026 | Download |
| 12846 | May 9, 2024 | Download |
| 07346 | Mar 15, 2024 | Download |
| 03846 | Feb 15, 2024 | Download |
| 00946 | Jan 11, 2024 | Download |
| 25745B | Sep 20, 2023 | Download |
| 25745A | Sep 20, 2023 | Download |
Frequently Asked Questions
What is complement activity (CH50 / hemolytic titer) and how is it tested?
How is Pel-Freez Biologicals' antibody-depleted complement made?
What's the difference between antibody-depleted human complement (ADHC), heat-inactivated ADHC (ADHC-HI) and antibody-depleted human serum (ADHS)?
- ADHC (antibody-depleted human complement) keeps high complement potency for assays that need functional complement.
- ADHC-HI is the same material heat-inactivated and CH50 tested to confirm no complement activity, for applications that need the other serum components but not complement.
- ADHS (antibody-depleted human serum) starts from normal human serum that was not collected to preserve complement; it is neither heat-inactivated nor CH50 tested, and serves as a negative matrix for dilution, QC samples, or cell culture where complement would inhibit growth.
Which immunoglobulins are removed from your antibody-depleted human products?
Are there residual antibodies in Pel-Freez Biologicals' antibody-depleted complement?
How is antibody-depleted human serum used as an assay control or matrix?
Show 2 more questions
What is the difference between pooled and single-donor products?
What is heat-inactivated serum and when should I use it?
Product References
- Salic acid protects nontypeable Haemophilus influenza from natural IgM and promotes survival in murine respiratory tract.
Jackson, M. D., Wong, S. M. & Akerley, B. J. Sialic acid protects nontypeable haemophilus influenzae from natural igm and promotes survival in murine respiratory tract. Infect. Immun. 89, (2021).
- Development of Complement Factor H–Based Immunotherapeutic Molecules in Tobacco Plants Against Multidrug-Resistant Neisseria gonorrhoeae
Shaughnessy, J. et al. Development of Complement Factor H–Based Immunotherapeutic Molecules in Tobacco Plants Against Multidrug-Resistant Neisseria gonorrhoeae. Front. Immunol. 11, 2680 (2020).
- Synthetic DNA Delivery of an Optimized and Engineered Monoclonal Antibody Provides Rapid and Prolonged Protection against Experimental Gonococcal Infection
Parzych, E. M. et al. Synthetic dna delivery of an optimized and engineered monoclonal antibody provides rapid and prolonged protection against experimental gonococcal infection. MBio 12, 1–13 (2021).
- Neisseria meningitidis urethritis outbreak isolates express a novel factor H binding protein variant that is a potential target of group B-directed meningococcal (MenB) …
Tzeng, Y. L. et al. Neisseria meningitidis urethritis outbreak isolates express a novel factor H binding protein variant that is a potential target of group B-Directed meningococcal (menb) vaccines. Infect. Immun. 88, (2020).
- Vaccination with Detoxified Leukocidin AB Reduces Bacterial Load in a Staphylococcus aureus Minipig Deep Surgical Wound Infection Model
Fernandez, J. et al. Vaccination with Detoxified Leukocidin AB Reduces Bacterial Load in a Staphylococcus aureus Minipig Deep Surgical Wound Infection Model . J. Infect. Dis. (2021).
- Preclinical efficacy of a lipooligosaccharide peptide mimic candidate gonococcal vaccine
Gulati, S. et al. Preclinical efficacy of a lipooligosaccharide peptide mimic candidate Gonococcal vaccine. MBio 10, (2019).
- Complement-Dependent Serum Bactericidal Assays for Neisseria gonorrhoeae
Gulati, S., Rice, P. A. & Ram, S. Complement-Dependent Serum Bactericidal Assays for Neisseria gonorrhoeae. in Methods in Molecular Biology vol. 1997 267–280 (Humana Press Inc., 2019).
- Development of Complement Factor H–Based Immunotherapeutic Molecules in Tobacco Plants Against Multidrug-Resistant Neisseria
Shaughnessy, J. et al. Development of Complement Factor H–Based Immunotherapeutic Molecules in Tobacco Plants Against Multidrug-Resistant Neisseria gonorrhoeae. Front. Immunol. 11, (2020).
